NSE filing, NSE: GRASIM. Summary written from the filing by ALFA Finder's alert engine.
Grasim Industries Ltd: key numbers
- Share price
- ₹2,981.40
- Market cap
- ₹2,02,891 Cr
- Revenue (annual)
- ₹1,75,431 Cr
- Net profit (annual)
- ₹4,966 Cr
- P/E (TTM)
- 35.6×Sector 32.4×
- Promoter holding
- 45.20%+1.46% QoQ
- FII holding
- 14.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Grasim Industries Ltd
All →Grasim Industries Board Meeting Date
Grasim Industries scheduled its Board meeting for 13 Nov 2026 to approve Q2 and H1 unaudited financial results. Trading window remains closed until 15 Nov 2026.
Grasim Industries Debt & Borrowing: ₹750 Cr
Grasim Industries repaid ₹750 Crore of Commercial Paper (ISIN INE047A14BE6) at maturity on 26 Oct 2026. Outstanding CP amount is now Nil.
- Value
- ₹750.0 Cr
Grasim Industries Legal & Regulatory
Grasim replied to exchange queries on a news item. The Bombay HC quashed the Rs 329 crore reassessment notice, with no demand or financial impact.
Grasim Industries Production Started
Grasim Industries has commenced commercial production at its Epichlorohydrin plant in Vilayat, Gujarat, with a capacity of 50 K TPA. This strengthens its downstream chlor-alkali derivatives portfolio.
- epichlorohydrin (ECH) manufacturing capacity
- 50000 TPA
Grasim Industries Other Announcement
Grasim Industries Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI listing regulations.
Grasim Industries Debt & Borrowing
Grasim Industries submitted its half-yearly statement of outstanding Non-Convertible Debentures as of 30th September 2026, complying with SEBI circular requirements for debt securities.
Other regulatory approval announcements
All →Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.